Leadership Team
Lloyd Mencinger
President/CEO
Virender K. Sharma, MD
Founder/CMO/Director
Greg Wilson, CPA
Chief Financial Officer
Scott McGill
VP Research & Development
Lloyd Mencinger
President/CEO
Lloyd Mencinger, MBA
President/CEO
Virender K. Sharma, MD
Founder/CMO/Director
Virender K. Sharma, MD
Founder/Chief Medical Officer/Director
Virender K. Sharma, MD, is a world-renowned physician with deep entrepreneurial experience in developing multiple innovative technologies in gastroenterology and endoscopy, with 32 patents currently issued and more than 30 pending.
He was responsible for the successful execution of a $70M-funding initiative, a European commercial launch, and a U.S.-based clinical trial during his tenure at EndoStim, Inc., developer of a revolutionary neurostimulation technology for gastroesophageal reflux disease. And under his leadership at SynerZ Medical, Inc., the company experienced one of the fastest acquisitions of gastrointestinal medtech companies in recent history after successful completion of animal trials for its obesity and diabetes therapy.
Dr. Sharma is Founder and Director of Arizona Center for Digestive Health and runs a clinical practice in Phoenix, Arizona. He is Board-certified in gastroenterology and hepatology and has authored more than 300 peer-reviewed articles and presentations. He is also a past Professor of Medicine and Vice Chair of GI Research at Mayo Clinic Arizona.
LinkedinGreg Wilson, CPA
Chief Financial Officer
Greg Wilson, MBA, CPA
Chief Financial Officer
Greg Wilson brings to Aqua Medical a career focused on navigating companies through the life science and biotechnology landscape, including serving as a consulting Chief Financial Officer for more than 50 early-stage ventures. He has guided numerous companies to successful exits, including Cytomx’s (CTMX) initial public offering, BARRX’s $400-million acquisition by Covidien (Medtronic), Afferent’s $1.25-billion acquisition by Merck, and Xros’s $3.2-billiion acquisition by Nortel. He also played a key role in assisting Ablexis Technologies in licensing its AlivaMab Mouse antibody drug discovery platform to a majority of the world’s top pharmaceutical manufacturers.
LinkedinScott McGill
VP Research & Development
Scott McGill, MBA
Vice President, Research & Development
Scott McGill leads Aqua Medical’s innovative future with a foundation based firmly in more than 25 years of medical device engineering and product development at early-stage clinical manufacturers. He has served as Vice President, Research and Development, for CardioProlific (acquired by Philips) and as Vice President, Product Development, for Serene Medical, Inc.
In addition to management expertise, his background is steeped in engineering and product development, including roles at Arkal Medical (Sr. Director, Device and Product Engineering); Primaeva Medical, acquired by Syneron Candela (Sr. Director Product Development); Percusurge, Inc., acquired by Medtronic (Project Manager, Research and Development); and Reflow, Inc., acquired by Fox Hollow Technologies (R&D Engineer).
Fund of the late
Pete Nicholas
Founder and Ex-Chairman
of Boston Scientific
Fund of the late
Pete Nicholas
Founder and Ex-Chairman
of Boston Scientific
Board of Directors
Greg Barrett
Chairman
William Dai
Director
Bill Starling
Director
Michael Blomeyer
Director
Greg Barrett
Chairman
Greg Barrett
Chairman
Greg Barrett provides valuable direction to Aqua Medical’s Board based on his 35 years of successfully guiding innovative companies toward lucrative acquisitions in gastroenterology, urology, cardiology, and surgery. His leadership is informed by roles as President and CEO of DFine (acquired by Merit Medical for ~$100 million); Chairman, President, and CEO of BARRX Medical (acquired by Covidien/Medtronic for $400 million); and President and CEO of ACMI Corp. (acquired by Gyrus/Olympus for $500 million).
He served as Boston Scientific’s Group President and Executive Vice President for Boston Scientific and as Vice President, Global Sales and Marketing, for Orthofix Corp. and Baxter Healthcare. He also served as Vice President of Marketing in the Cardiosurgery Division of C.R. Bard Corp.. He currently serves on the Board of Directors of BTG plc (acquired by Boston Scientific for $4.2 billion), Cutera, and Barosense.
William Dai
Director
William Dai
Director
As Founding Managing Partner of ShangBay Capital, LLC, William Dai was pivotal in closing the final equity round in Aqua Medical’s $15.5-million Series A funding. His expertise in venture capital and private equity is based in a career spanning the globe. He has served as CFO of two industry giants in China: ShangPharma Corp., the second largest CRO in China, and China Nepstar Corp., the largest pharmaceutical retail operation in China.
With than 20 years of experience in executive roles in the biotechnology industry, including serving as CFO and Vice-Chair of the Executive Committee at Microport Scientific Corp., one of the largest medical device manufacturers in China, and guiding Boston Scientific’s significant expansion in the Chinese market as CFO, he is renowned for his authoritative direction and expertise.
Bill Starling
Director
Bill Starling
Director
Bill Starling is co-founder of Advanced Cardiovascular Systems, which was acquired by Lilly/Guidant/Abbott, and former President & CEO of Cardiac Pathways, which was acquired by Boston Scientific following successful completion of its IPO. He is also co-founder of Bioerodible Vascular Solutions (acquired by Guidant/Abbott) and served as Director of iRhythm Technologies (a Stanford BioDesign spinout) through its IPO.
He currently serves as CEO of Conveyor Cardiovascular and is Board Chairman of InnAVasc, a spinout from Duke University Medical Center. His depth of expertise includes raising over $280M in private and public capital. The startup companies he co-founded represent $4B in annual revenues today.
He is steeped in successful navigation of the challenges unique to start-ups. Under his guidance as CEO of Synecor business generator, he co-founded BaroSense, TransEnterix, Interventional Autonomics, and NeuroTronik. He has served as Managing Director of Synergy Life Science Partners, a $143M venture capital partnership, since its founding. He currently shares his clinical management expertise on the Board of Advisors at Stanford Stroke Center and the Board of Advisors at the University of North Carolina’s Kenan-Flagler Business School.
Michael Blomeyer
Director
Michael Blomeyer
Director
Michael Blomeyer is General Partner and Co-Founder of ForMED Ventures, directing early-stage health and medtech companies primarily in Israel, Taiwan, and the U.S. He also advances global development and strategy for these companies through his role as President of New Deantronics and E Surgical.
His depth of global experience includes leading operations and market expansion as General Manager for Hewlett-Packard Medical Asia-Pacific, as well as serving as CEO for Quinton Instruments and Beckman Instruments. His consultation and acumen have been integral to the successful evolution of numerous companies and charitable projects worldwide.